Therapeutic Potential of Tauroursodeoxycholic Acid for the Treatment of Osteoporosisopen access
- Authors
- Ahn, Tae-Keun; Kim, Kyoung-Tae; Joshi, Hari Prasad; Park, Kwang Hwan; Kyung, Jae Won; Choi, Un-Yong; Sohn, Seil; Sheen, Seung-Hun; Shin, Dong-Eun; Lee, Soo-Hong; Han, In-Bo
- Issue Date
- Jun-2020
- Publisher
- MDPI
- Keywords
- osteoblast; osteoporosis; bone turnover biomarkers; matrix mineralization; bone histomorphometry
- Citation
- INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.21, no.12, pp 1 - 15
- Pages
- 15
- Indexed
- SCIE
SCOPUS
- Journal Title
- INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Volume
- 21
- Number
- 12
- Start Page
- 1
- End Page
- 15
- URI
- https://scholarworks.dongguk.edu/handle/sw.dongguk/6562
- DOI
- 10.3390/ijms21124274
- ISSN
- 1661-6596
1422-0067
- Abstract
- Tauroursodeoxycholic acid (TUDCA) is a US FDA-approved hydrophilic bile acid for the treatment of chronic cholestatic liver disease. In the present study, we investigate the effects of TUDCA on the proliferation and differentiation of osteoblasts and its therapeutic effect on a mice model of osteoporosis. Following treatment with different concentrations of TUDCA, cell viability, differentiation, and mineralization were measured. Three-month-old female C57BL/6 mice were randomly divided into three groups (n= 8 mice per group): (i) normal mice as the control group, (ii) ovariectomy (OVX) group (receiving phosphate-buffered saline (PBS) treatment every other day for 4 weeks), and (iii) OVX group with TUDCA (receiving TUDCA treatment every other day for 4 weeks starting 6 weeks after OVX). At 11 weeks post-surgery, serum levels of procollagen type I N-terminal propeptides (PINP) and type I collagen crosslinked C-telopeptides (CTX) were measured, and all mice were sacrificed to examine the distal femur by micro-computed tomography (CT) scans and histology. TUDCA (100 nM, 1 mu M) significantly increased the proliferation and viability of osteoblasts and osteoblast differentiation and mineralization when used in vitro. Furthermore, TUDCA neutralized the detrimental effects of methylprednisolone (methylprednisolone-induced osteoblast apoptosis). In the TUDCA treatment group the PINP level was higher and the CTX level was lower, but these levels were not significantly different compared to the PBS treatment group. Micro-CT and histology showed that the TUDCA treatment group preserved more trabecular structures in the distal femur compared to the PBS treatment group. In addition, the TUDCA treatment group increased the percentage bone volume with respect to the total bone volume, bone mineral density, and mice distal femur trabeculae compared with the PBS treatment group. Taken together, our findings suggest that TUDCA may provide a favorable effect on bones and could be used for the prevention and treatment of osteoporosis.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Life Science and Biotechnology > Department of Biomedical Engineering > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.